Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, reviews advances in non-metastatic castration-resistant prostate cancer as well as agents for this indication that have been found to reduce the incidence of metastasis as well as result in reduced mortality. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).